Revolve Wealth Partners LLC Has $1.69 Million Stake in Johnson & Johnson (NYSE:JNJ)

Revolve Wealth Partners LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 86.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,440 shares of the company’s stock after buying an additional 4,840 shares during the quarter. Revolve Wealth Partners LLC’s holdings in Johnson & Johnson were worth $1,692,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Shilanski & Associates Inc. acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at about $427,000. Dakota Community Bank & Trust NA increased its holdings in Johnson & Johnson by 20.6% in the first quarter. Dakota Community Bank & Trust NA now owns 1,498 shares of the company’s stock worth $237,000 after purchasing an additional 256 shares in the last quarter. Allied Investment Advisors LLC lifted its stake in Johnson & Johnson by 4.5% in the first quarter. Allied Investment Advisors LLC now owns 57,045 shares of the company’s stock valued at $9,024,000 after buying an additional 2,431 shares during the period. Aurora Investment Managers LLC. boosted its holdings in shares of Johnson & Johnson by 3.5% during the 1st quarter. Aurora Investment Managers LLC. now owns 3,745 shares of the company’s stock worth $592,000 after buying an additional 125 shares in the last quarter. Finally, Tealwood Asset Management Inc. grew its position in shares of Johnson & Johnson by 1.0% during the 1st quarter. Tealwood Asset Management Inc. now owns 15,634 shares of the company’s stock worth $2,473,000 after buying an additional 148 shares during the period. Institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.4 %

Shares of Johnson & Johnson stock opened at $165.12 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The stock has a fifty day simple moving average of $162.98 and a 200 day simple moving average of $154.69. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a market capitalization of $397.39 billion, a P/E ratio of 10.29, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same quarter in the prior year, the business posted $2.66 EPS. The business’s revenue was up 5.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Johnson & Johnson will post 10 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.00%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Analysts Set New Price Targets

JNJ has been the topic of several research analyst reports. Citigroup increased their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday. Wells Fargo & Company increased their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday. The Goldman Sachs Group reduced their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, Sanford C. Bernstein raised their price objective on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Six research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $175.93.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.